Yichen Zhang

机构：King University, Peking University, Purdue University West Lafayette, Beijing Normal University, Royal Pharmaceutical Society, University of California San Diego, Chinese Institute for Brain Research, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Southern Medical University · ORCID：0000-0001-7093-1044

发表论文 84 篇 · 总被引 1220 次 · h-index 20

代表论文

• Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis (2024 · The Lancet Oncology · 被引 45)
• Prevalence of aggressive care among patients with cancer near the end of life: a systematic review and meta-analysis (2024 · EClinicalMedicine · 被引 44)
• Inhalable biohybrid microrobots: a non-invasive approach for lung treatment (2025 · Nature Communications · 被引 40)
• Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer (2024 · Journal of Translational Medicine · 被引 16)
• Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020 (2024 · The Lancet Regional Health - Western Pacific · 被引 11)
• Edible bird's nest regulates glucose and lipid metabolic disorders via the gut–liver axis in obese mice (2024 · Food & Function · 被引 11)